The target identification approach ‘DEFINIT', developed and utilized in the current study appreciated the destructive liaison between the oncogenic driver BRAF(V600E) and often concomitantly amplified MITF14 to identify combinatorial MAPK signaling and AURKA inhibition as more effective therapeutic approach in melanoma. Here, BRAF is linked to melanoma.